Contents:

EXECUTIVE SUMMARY Scope Datamonitor insight into the diabetes market Key metrics TABLE OF CONTENTS PATIENT POTENTIAL Definition of disease Future trends in the incidence and prevalence of diabetes Diagnosis, treatment and compliance rates Diagnosis Treatment Compliance rates Unmet needs in diabetes Drug delivery Efficacy Side effects Compliance Awareness and education Glucose monitoring R&D APPROACH Classification of pipeline products Insulins Sulphonylureas Biguanides Glitazones Alpha glucosidase inhibitors (AGI) Prandial glucose regulators (PGR) Summary Definition of current ‘gold standard’ / comparator therapies Clinical trials endpoints in diabetes Control of average blood glucose levels (HbA1c) Control of fasting and postprandial glucose levels Reduction in incidents of iatrogenic hypoglycemia Reduction in development of diabetic complications Reduction in diabetic-associated mortality Prevention of weight gain Critique of clinical trial design in diabetes DIABETES PIPELINE OVERVIEW Pipeline overview Key drug delivery strategies in diabetes Key licensing strategies and licensing opportunities in diabetes Pipeline analysis by class Pipeline analysis by individual company LATE STAGE DRUG ANALYSIS Comparison of key compounds in diabetes Drug delivery formulation and its effect on compliance Efficacy and its effect on compliance Side effects and their effects on compliance Marketing strength Insulin drug profiles Overview table for insulin NovoMix 30 (injectable insulin) Insulin Detemir (NN 304) (injectable insulin) Exubera/HMR 4006 (inhaled insulin) AeroDose (inhaled insulin) AERx (inhaled insulin) AI401 (oral insulin) M2 (oral insulin) Macrulin (oral insulin) Oralin (oral insulin) Comparative analysis of the insulin class Drug delivery formulation Efficacy Side effects Overall performance Comparative analysis of inhalation insulins Drug delivery formulation Efficacy and side effects Marketing strength Comparative analysis of oral insulins Drug delivery formulation Efficacy and side effects Marketing strength Biguanides drug profiles Overview table for biguanides Metformin GR Metformin XT/ADX 155 Metformin/miglitol combination therapy Comparative analysis of biguanides Drug delivery formulation Efficacy Side effects Marketing strength Overall performance Glitazones, AGI and PGR Overview of glitazone, AGI and PRG drug classes MCC–555 (glitzone) BAY o 1248/MKC 542/emiglitate (AGI) KAD–1229/mitiglinide (PRG) Hormonal (non-insulin) drug profiles Overview of hormonal (non-insulin) drugs Ergoset – development on hold Symlin (pramlintide acetate - amylin hormone analog) SomatoKine (novel insulin-like growth factor) Leptin (hormone) RF 1051 (DHEA Phosphocholine) Betatropin (recombinant GLP-1) Exendin-4/AC2993 (GLP-1 like peptide) Comparative analysis of hormonal (non-insulin) drugs Drug delivery formulation Efficacy Side effects Marketing strength Overall performance Insulin sensitizers Overview of insulin sensitizers NN 622/DRF 2725 JTT–501 (PNU-716-MET-0096/PNU-182716) INS 1/D-chiroinositol carbohydrate derivative CLX–0901 Comparative analysis of insulin sensitizer class Drug delivery formulation Efficacy Side effects Marketing strength Overall performance Enzyme inhibitors Overview of enzyme inhibitors Xenical/oristat (lipase inhibitor) NVP–DPP 728/LAF 237 (dipeptidyl peptidase inhibitor) P32/98 (dipeptidyl petidase inhibitor) Comparative analysis of enzyme inhibitors Drug delivery formulation Efficacy Side effects Marketing strength Overall performance Others Overview of others BAY 27-9955 (glucagon receptor antagonist) DiaPep277 (immune system) Recently discontinued development projects GI262570 INNOVATIVE EARLY STAGE PROJECTS Key phase I and preclinical compounds in diabetes Beta-3 adrenoceptors Growth hormone releasing hormone (GHRH) analogues Glycogen phosphorylase inhibitors (GPI) Cell technology Retinoid X receptor modulators Others THE FUTURE DECODED Methodology Predicting initial market share Forecasting future growth Influencing factors Market drivers in diabetes Prospective drug launches in diabetes Launch forecast methodology Forecast launches in diabetes from 2001 to 2008 Key R&D product forecasts Xenical Mitiglinide (KAD–1229) Symlin Metformin XT/GR NovoMix 30 Betatropin Exubera Insulin Detemir AERx Oralin Somatokine M2 and Macrulin LAF 237 APPENDIX Datamonitor's Immune Disorders and Inflammation (IDI) Business Unit Contributing experts Table of tables Table of figures Bibliography R&D research methodology Introduction Hypothesis formulation Hypothesis testing Data verification and quality control Quantification of data reliability